Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 94

Related Citations for PubMed (Select 22819510)

1.

Epidemiology of Streptococcus pneumoniae.

Varon E.

Med Mal Infect. 2012 Aug;42(8):361-5. doi: 10.1016/j.medmal.2012.04.002. Epub 2012 Jul 21.

PMID:
22819510
2.

Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae.

Dagan R.

Clin Microbiol Infect. 2009 Apr;15 Suppl 3:16-20. doi: 10.1111/j.1469-0691.2009.02726.x. Review.

4.

Serotypes 1, 7F and 19A became the leading causes of pediatric invasive pneumococcal infections in Portugal after 7 years of heptavalent conjugate vaccine use.

Aguiar SI, Brito MJ, Gonçalo-Marques J, Melo-Cristino J, Ramirez M.

Vaccine. 2010 Jul 19;28(32):5167-73. doi: 10.1016/j.vaccine.2010.06.008. Epub 2010 Jun 15.

PMID:
20558247
5.

Baseline epidemiology of Streptococcus pneumoniae serotypes in Canada prior to the introduction of the 13-valent pneumococcal vaccine.

Adam HJ, Karlowsky JA, Nichol KA, Gilmour MW, Hoban DJ, Embree J, Zhanel GG.

Microb Drug Resist. 2012 Apr;18(2):176-82. doi: 10.1089/mdr.2011.0197. Epub 2011 Dec 28.

PMID:
22204595
6.

Serotype replacement in perspective.

Dagan R.

Vaccine. 2009 Aug 21;27 Suppl 3:C22-4. doi: 10.1016/j.vaccine.2009.06.004. Epub 2009 Jun 21.

PMID:
19545935
7.

Epidemiology of Streptococcus pneumoniae in France before introduction of the PCV-13 vaccine.

Grall N, Hurmic O, Al Nakib M, Longo M, Poyart C, Ploy MC, Varon E, Raymond J; ORP Ile de France Ouest.

Eur J Clin Microbiol Infect Dis. 2011 Dec;30(12):1511-9. doi: 10.1007/s10096-011-1251-9. Epub 2011 Apr 18.

PMID:
21499971
8.

[Epidemiological features of invasive pneumococcal disease before and after the introduction of pneumococcal conjugate vaccine in Gran Canaria (Canary Islands)].

Artiles F, Horcajada I, Cañas AM, Alamo I, Bordes A, González A, Santana M, Lafarga B.

Enferm Infecc Microbiol Clin. 2009 Jan;27(1):14-21. doi: 10.1016/j.eimc.2008.03.001. Epub 2009 Jan 9. Spanish.

PMID:
19217998
9.

Regional differences in serotype distribution, pneumococcal vaccine coverage, and antimicrobial resistance of invasive pneumococcal disease among German federal states.

Imöhl M, Reinert RR, van der Linden M.

Int J Med Microbiol. 2010 Apr;300(4):237-47. doi: 10.1016/j.ijmm.2009.05.005. Epub 2009 Jul 14.

PMID:
19604721
10.

Management of antibiotic-resistant Streptococcus pneumoniae infections and the use of pneumococcal conjugate vaccines.

Picazo JJ.

Clin Microbiol Infect. 2009 Apr;15 Suppl 3:4-6. doi: 10.1111/j.1469-0691.2009.02723.x. Review.

PMID:
19366362
11.

Ten-year surveillance of pneumococcal infections in Temuco, Chile: implications for vaccination strategies.

Inostroza J, Illesca V, Reydet P, Vinet AM, Ossa G, Muñoz S, Thompson T, Sorensen RU.

Clin Vaccine Immunol. 2007 Jun;14(6):660-4. Epub 2007 Mar 28.

13.

Possibility of application of new pneumococcal conjugate vaccines in children in Slovenia.

Paragi M, Kolman J, Kraigher A, Cizman M, Gubina M, Ribic H; Slovenian Meningitis Study Group.

Vaccine. 2003 Dec 1;21(32):4708-14.

PMID:
14585680
14.

New insights on pneumococcal disease: what we have learned over the past decade.

Dagan R.

Vaccine. 2009 Aug 21;27 Suppl 3:C3-5. doi: 10.1016/j.vaccine.2009.06.002. Epub 2009 Jun 23.

PMID:
19552985
15.

The coming of age of niche vaccines? Effect of vaccines on resistance profiles in Streptococcus pneumoniae.

McGee L.

Curr Opin Microbiol. 2007 Oct;10(5):473-8. Epub 2007 Oct 23. Review.

PMID:
17936680
16.

Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States.

Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B; Active Bacterial Core Surveillance Team.

J Infect Dis. 2005 Dec 1;192(11):1988-95. Epub 2005 Nov 1.

17.

Incidence of macrolide resistance in Streptococcus pneumoniae after introduction of the pneumococcal conjugate vaccine: population-based assessment.

Stephens DS, Zughaier SM, Whitney CG, Baughman WS, Barker L, Gay K, Jackson D, Orenstein WA, Arnold K, Schuchat A, Farley MM; Georgia Emerging Infections Program.

Lancet. 2005 Mar 5-11;365(9462):855-63.

PMID:
15752529
18.

Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.

Kyaw MH, Lynfield R, Schaffner W, Craig AS, Hadler J, Reingold A, Thomas AR, Harrison LH, Bennett NM, Farley MM, Facklam RR, Jorgensen JH, Besser J, Zell ER, Schuchat A, Whitney CG; Active Bacterial Core Surveillance of the Emerging Infections Program Network.

N Engl J Med. 2006 Apr 6;354(14):1455-63. Erratum in: N Engl J Med. 2006 Aug 10;355(6):638.

19.

Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.

Pelton SI, Huot H, Finkelstein JA, Bishop CJ, Hsu KK, Kellenberg J, Huang SS, Goldstein R, Hanage WP.

Pediatr Infect Dis J. 2007 Jun;26(6):468-72.

PMID:
17529860
20.

Changing serotypes causing childhood invasive pneumococcal disease: Massachusetts, 2001-2007.

Hsu KK, Shea KM, Stevenson AE, Pelton SI; Massachusetts Department of Public Health.

Pediatr Infect Dis J. 2010 Apr;29(4):289-93. doi: 10.1097/INF.0b013e3181c15471.

PMID:
19935447
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk